This invention provides isolated and characterized secreted molecules from probiotic bacteria for use in compositions and methods for the treatment and/or prevention of infection by harmful pathogenic bacteria. The isolated secreted molecules can also be used in nutritional or medical food products which provide probiotics to the gastrointestinal tract of a mammal.

This invention provides isolated and characterized secreted molecules from probiotic bacteria for use in compositions and methods for the treatment and/or prevention of infection by harmful pathogenic bacteria. The isolated secreted molecules can also be used in nutritional or medical food products which provide probiotics to the gastrointestinal tract of a mammal.

The present invention relates generally to the field of compositions comprising myo- inositol for use in the prevention of post partum haemorrhage (PPH) and disorders and/or conditions linked thereto. The composition may be a nutritional composition, for example a maternal nutrition composition. The composition may be specifically designed to provide optimized nutrition to a woman desiring to get pregnant, to a pregnant woman or to a woman who gave birth.

The present invention relates generally to the field of compositions comprising myo- inositol for use in the prevention of post partum haemorrhage (PPH) and disorders and/or conditions linked thereto. The composition may be a nutritional composition, for example a maternal nutrition composition. The composition may be specifically designed to provide optimized nutrition to a woman desiring to get pregnant, to a pregnant woman or to a woman who gave birth.

The present invention relates generally to the field of compositions comprising myo- inositol for use in the prevention of post partum haemorrhage (PPH) and disorders and/or conditions linked thereto. The composition may be a nutritional composition, for example a maternal nutrition composition. The composition may be specifically designed to provide optimized nutrition to a woman desiring to get pregnant, to a pregnant woman or to a woman who gave birth.

A method useful for providing a phytonutrient to a subject via mediation of the subject’s microbiome is disclosed. The method includes administering a phytofunctional composition to a subject change the phytonutrient producer status of the subject. The method may also include identifying a phytonutrient producer status of the subject by assessing a level of at least one of a preselected phytonutrient and a preselected phytonutrient precursor compound within the subject. A phytofunctional composition useful in the method is also disclosed, and comprises a phytonutrient precursor compound and an active agent. The active agent comprises a probiotic and/or a prebiotic, and is adapted to mediate production of the preselected phytonutrient in the gastrointestinal tract of the subject, thereby changing the phytonutrient producer status of the subject.

A method useful for providing a phytonutrient to a subject via mediation of the subject’s microbiome is disclosed. The method includes administering a phytofunctional composition to a subject change the phytonutrient producer status of the subject. The method may also include identifying a phytonutrient producer status of the subject by assessing a level of at least one of a preselected phytonutrient and a preselected phytonutrient precursor compound within the subject. A phytofunctional composition useful in the method is also disclosed, and comprises a phytonutrient precursor compound and an active agent. The active agent comprises a probiotic and/or a prebiotic, and is adapted to mediate production of the preselected phytonutrient in the gastrointestinal tract of the subject, thereby changing the phytonutrient producer status of the subject.

A method useful for providing a phytonutrient to a subject via mediation of the subject’s microbiome is disclosed. The method includes administering a phytofunctional composition to a subject change the phytonutrient producer status of the subject. The method may also include identifying a phytonutrient producer status of the subject by assessing a level of at least one of a preselected phytonutrient and a preselected phytonutrient precursor compound within the subject. A phytofunctional composition useful in the method is also disclosed, and comprises a phytonutrient precursor compound and an active agent. The active agent comprises a probiotic and/or a prebiotic, and is adapted to mediate production of the preselected phytonutrient in the gastrointestinal tract of the subject, thereby changing the phytonutrient producer status of the subject.

This invention is referred to the field of medicine, namely preventative treatment, and may be used as a means of synergetic minimization of negative impact of flights on human health (brain, stomach, lungs, blood vessels, heart etc.) with application of known substances and medicines with newly discovered pharmacological properties in new conditions. The ultimate technical solution of this invention would be synergetic minimization of negative impact of flying on human health without foot swelling, belching, jet-lag, tiredness and fatigue etc. The claimed technical result is achieved by the method of synergetic minimization of negative impact of air flights on human health, including consumption of substances that improve osmotic concentration of blood plasma, in the form of oral rehydration solution, split into two intakes as a minimum, first intake in the amount of at least 0.3 liters up to 1 liter before boarding and further during the flight from half an hour to 2 hours at least 0.3 liters to 1 liter and on as-needed basis.

This invention is referred to the field of medicine, namely preventative treatment, and may be used as a means of synergetic minimization of negative impact of flights on human health (brain, stomach, lungs, blood vessels, heart etc.) with application of known substances and medicines with newly discovered pharmacological properties in new conditions. The ultimate technical solution of this invention would be synergetic minimization of negative impact of flying on human health without foot swelling, belching, jet-lag, tiredness and fatigue etc. The claimed technical result is achieved by the method of synergetic minimization of negative impact of air flights on human health, including consumption of substances that improve osmotic concentration of blood plasma, in the form of oral rehydration solution, split into two intakes as a minimum, first intake in the amount of at least 0.3 liters up to 1 liter before boarding and further during the flight from half an hour to 2 hours at least 0.3 liters to 1 liter and on as-needed basis.